Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)
Cancer · 2024-06 · 130 (11) · 1930-1939
DOI: 10.1002/cncr.35221 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer, online erschienen am 10.02.2024. Verfasst von Celestia S Higano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium, Taxoids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer HealthCare Pharmaceuticals.
Abstract (Originalsprache)
Background
Radium‐223 and taxane chemotherapy each improve survival of patients with metastatic castration‐resistant prostate cancer (mCRPC). Whether the radium‐223–taxane sequence could extend survival without cumulative toxicity was explored.
Methods
The global, prospective, observational REASSURE study (NCT02141438) assessed real‐world safety and effectiveness of radium‐223 in patients with mCRPC. Using data from the prespecified second interim analysis (data cutoff, March 20, 2019), hematologic events and overall survival (OS) were evaluated in patients who were chemotherapy‐naive at radium‐223 initiation and subsequently received taxane chemotherapy starting ≤90 days (“immediate”) or >90 days (“delayed”) after the last radium‐223 dose.
Results
Following radium‐223 therapy, 182 patients received docetaxel (172 [95%]) and/or cabazitaxel (44 [24%]); 34 patients (19%) received both. Seventy‐three patients (40%) received immediate chemotherapy and 109 patients (60%) received delayed chemotherapy. Median time from last radium‐223 dose to first taxane cycle was 3.6 months (range, 0.3–28.4). Median duration of first taxane was 3.7 months (range, 0–22.0). Fourteen patients (10 in the immediate and four in the delayed subgroup) had grade 3/4 hematologic events during taxane chemotherapy, including neutropenia in two patients in the delayed subgroup and thrombocytopenia in one patient in each subgroup. Median OS was 24.3 months from radium‐223 initiation and 11.8 months from start of taxane therapy.
Conclusions
In real‐world clinical practice settings, a heterogeneous population of patients who received sequential radium‐223–taxane therapy had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Thus, taxane chemotherapy is a feasible option for those who progress after radium‐223. Clinical Trial Registration ClinicalTrials.gov identifier NCT02141438. Plain Language Summary Radium‐223 and chemotherapy are treatment options for metastatic prostate cancer, which increase survival but may affect production of blood cells as a side effect. We wanted to know what would happen if patients received chemotherapy after radium‐223. Among the 182 men treated with radium‐223 who went on to receive chemotherapy, only two men had severe side effects affecting white blood cell production (neutropenia) during chemotherapy. On average, the 182 men lived for 2 years after starting radium‐223 and 1 year after starting chemotherapy. In conclusion, patients may benefit from chemotherapy after radium‐223 treatment without increasing the risk of side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- Department of Nuclear Medicine, University Hospital Sussex, NHS Foundation Trust, and Brighton and Sussex Medical School, University of Sussex and Brighton, Brighton, UK.
- Oncology Department Uro-Oncology Team, The Christie NHS Foundation Trust, Manchester, UK.
- Urology, GU Research Network - Wichita Urology Group, Wichita, Kansas, USA.
- Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
- Department of Urology CB62, University Medical Center Groningen, Groningen, Netherlands.
ORCID-Profile: Celestia S Higano, Oliver Sartor
Förderung
- Bayer HealthCare Pharmaceuticals
Zitieren
APA
Higano, C. S., Dizdarevic, S., Logue, J., Richardson, T., George, S., de Jong, I., Tomaszewski, J. J., Saad, F., Miller, K., Meltzer, J., Sandström, P., Verholen, F., Tombal, B., & Sartor, O. (2024). Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE). Cancer, 130(11), 1930-1939. https://doi.org/10.1002/cncr.35221
Vancouver
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, et al. Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE). Cancer. 2024;130(11):1930-1939. doi:10.1002/cncr.35221
BibTeX
@article{Higano2024,
author = {Higano, Celestia S and Dizdarevic, Sabina and Logue, John and Richardson, Timothy and George, Saby and de Jong, Igle and Tomaszewski, Jeffrey J and Saad, Fred and Miller, Kurt and Meltzer, Jeffrey and Sandström, Per and Verholen, Frank and Tombal, Bertrand and Sartor, Oliver},
title = {Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)},
journal = {Cancer},
year = {2024},
volume = {130},
number = {11},
pages = {1930--1939},
doi = {10.1002/cncr.35221}
}
EUVIMED